Spermosens accelerates its US business development activities in collaboration with Scan MedPartners

Spermosens is accelerating its business development activities and has entered into an agreement with US based Scan MedPartners as its business development advisor to identify and attract potential strategic and commercial partners in North America with a special focus on the US market.

As previously communicated, Spermosens is focused on securing licensing and co-development partners for its first of kind automated sperm diagnostic device JUNO-Checked. In line with this effort, Spermosens today announces a collaboration with Scan MedPartners, thereby significantly strengthening the company's business development capabilities. The collaboration will commence mid-July, 2024.

The US market is one of the world's three largest markets for IVF. In the United States, over 413,776 cycles in assisted reproductive technology (ART) were conducted at 453 reporting clinics in 2021, according to the Centers for Disease Control and Prevention (CDC[1]), in 2021. The in vitro fertilization (IVF) market size in the United States was valued at $4.9 billion in 2020 and is expected to reach $5.6 billion by 2027[2].

Spermosens has received patent protection for its medical device including the biosensor, and its use for the selection of sperm suitable for In Vitro Fertilization (IVF treatment). The US 11,782,052 patent provides the opportunity for exclusivity in the US market until August 23, 2039.

Scan MedPartners, an Orange County, CA US based Go-To-Market Consulting firm, provides commercial acceleration services via qualified US partner companies, willing to invest in the commercialization of disruptive MedTech & Life Science start-ups primarily based out of Scandinavia.

"We are very pleased to enter into a collaboration with Scan MedPartners, who will be valuable to us in securing strategic partners for our unique product for improving fertility treatment. With Scan MedPartner’s extensive experience and network in life science field, combined with the strong results for JUNO-Checked, we see many interesting business opportunities," says Tore Duvold, CEO of Spermosens.

“We are excited to collaborate with Spermosens and introduce their groundbreaking diagnostic platform technology, to improve outcomes for a currently underserved patient group in the US market," says Arne Madsen, President at Scan MedPartners, LLC.

For more information, please contact 

Tore Duvold, CEO

info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com

Tags: